2025-02-15 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**0. Executive Summary:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  This report analyzes LLY's performance against the S&P 500 (VOO), considering its recent price movements, financial indicators (RSI, PPO), earnings, and financial statements.  LLY has significantly outperformed VOO, showing strong growth but also exhibiting some recent price volatility.

**1. Performance Comparison with S&P 500 (VOO):**

Eli Lilly and Co. is a global pharmaceutical company specializing in the research, development, and manufacturing of pharmaceutical products.

* **LLY Cumulative Return:** 611.98%
* **VOO Cumulative Return:** 121.84%
* **Return Difference:** 490.1%
* **Relative Divergence:** 78.1% (This indicates LLY's performance is in the 78th percentile relative to its historical performance compared to VOO, not necessarily 78% better.)

The provided data shows a substantial outperformance of LLY compared to the S&P 500 over the analyzed period.  However, the relative divergence metric suggests the current outperformance is high relative to historical values.  The alpha and beta values fluctuate, indicating varying levels of market sensitivity and outperformance over different time periods. Notably, the CAGR (Compound Annual Growth Rate) remains strong across all periods.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 9.0% | 4.3% | -19.0% | -0.0 | 67.9 |
| 2016-2018  | 47.0% | 4.3% | 29.0% | 0.0 | 95.4 |
| 2017-2019  | 60.0% | 8.7% | 29.0% | 1.1 | 110.8 |
| 2018-2020  | 90.0% | 11.1% | 62.0% | 0.3 | 145.2 |
| 2019-2021  | 145.0% | 11.1% | 74.0% | 0.2 | 241.1 |
| 2020-2022  | 196.0% | 11.1% | 188.0% | 0.2 | 323.7 |
| 2021-2023  | 300.0% | 10.8% | 277.0% | 0.3 | 520.8 |
| 2022-2024  | 396.0% | 11.1% | 363.0% | 0.3 | 694.3 |
| 2023-2025  | 368.0% | 11.1% | 306.0% | 0.3 | 759.3 |


**2. Recent Price Movement:**

* **Closing Price:** $844.27
* **Previous Close:** $870.36
* **Change:** -$26.09 ( -2.99%)
* **5-day Moving Average:** $864.60
* **20-day Moving Average:** $818.80
* **60-day Moving Average:** $792.88

The price shows a recent downward trend, as indicated by the closing price being below all three moving averages.  The substantial negative daily change (-2.99%) warrants further investigation into potential market factors.


**3. Technical Indicators and Expected Return:**

* **RSI:** 61.73 (Slightly above neutral; not overbought)
* **PPO:** 0.45 (Positive; suggesting bullish momentum)
* **20-day Relative Divergence Change:** -4.9% (Short-term downward trend)
* **Expected Return (vs. S&P 500, long-term):** 105.1%

The RSI and PPO indicators suggest a generally positive outlook, although the recent price drop and negative relative divergence suggest caution.  The high expected return indicates significant potential for outperformance over the long term, assuming current trends continue.  The negative daily price change of -$26.09 (-2.99%) highlights a recent period of price correction.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-10-30 | $1.08  | $11.44 B       |
| 2024-08-08 | $3.29  | $11.30 B       |
| 2024-04-30 | $2.49  | $8.77 B        |
| 2023-11-02 | -$0.06 | $9.50 B        |
| 2024-10-30 | -$0.06 | $9.50 B        |

Earnings show volatility, with significant swings in EPS.  Revenue remains relatively stable, except for a dip in Q1 2024. Note that there seems to be a data duplication for Oct 30th. This inconsistency requires clarification.  Further analysis is needed to determine the drivers behind these fluctuations.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $11.44B | 81.02%        |
| 2024-06-30 | $11.30B | 80.80%        |
| 2024-03-31 | $8.77B  | 80.91%        |
| 2023-12-31 | $9.35B  | 80.88%        |
| 2023-09-30 | $9.50B  | 80.42%        |

**Capital and Profitability:**

| Quarter | Equity   | ROE       |
|---------|----------|-----------|
| 2024-09-30 | $14.24B | 6.81%     |
| 2024-06-30 | $13.56B | 21.88%    |
| 2024-03-31 | $12.81B | 17.51%    |
| 2023-12-31 | $10.77B | 20.33%    |
| 2023-09-30 | $11.22B | -0.51%    |

Revenue remains consistently strong, with high profit margins.  ROE shows some volatility, but remains generally positive, indicating strong profitability.  The negative ROE in Q3 2023 requires further investigation.


**6. Overall Conclusion:**

LLY has historically significantly outperformed the S&P 500, showing strong growth potential.  Recent price action suggests a potential short-term correction.  While long-term prospects look positive based on high expected returns and generally strong financial statements, investors should monitor recent earnings volatility and the reasons behind the recent price decline.  Further investigation is needed to resolve data inconsistencies, especially within the recent earnings and the duplicate entry for October 30th, 2024. A more in-depth analysis of individual product performance and market factors impacting LLY's price would provide a more comprehensive assessment.
